Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Pépin, David ^a,b   Shao, Zhong Qi ^c   Huppé, Geneviève ^c   Wakefield, Andrea ^c   Chu, Chee Wui ^c   Sharif, Zahra ^a,b   Vanderhyden, Barbara C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 10; KALLIKREIN 13; KALLIKREIN 14; KALLIKREIN 5; KALLIKREIN 6; NEUROPSIN; RECOMBINANT KALLIKREIN 10; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER SCREENING; CARCINOGENICITY; CELL CLONE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KALLIKREINS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 81055140912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026075     Document Type: Article

References (64)

1. Yousef GM, Obiezu CV, Luo L-Y, Magklara A, Borgoño CA, et al. (2005) Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem 39: 11-79.
2. Paliouras M, Diamandis EP, (2006) The kallikrein world: an update on the human tissue kallikreins. Biol Chem 387: 643-652 doi:10.1515/BC.2006.083.
3. Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, et al. (2007) Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem 282: 31852-31864 doi:10.1074/jbc.M705190200.
4. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, et al. (2006) Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem 281: 12743-12750 doi:10.1074/jbc.M600326200.
5. Yousef GM, Kishi T, Diamandis EP, (2003) Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 329: 1-8.
6. Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, et al. (2004) Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J 18: 920-922 doi:10.1096/fj.03-1212fje.
7. Colman RW, (1999) Plasma and tissue kallikrein in arthritis and inflammatory bowel disease. Immunopharmacology 43: 103-108.
8. Cassim B, Mody G, Bhoola K, (2002) Kallikrein cascade and cytokines in inflamed joints. Pharmacol Ther 94: 1-34.
9. Colman RW, Sartor RB, Adam AA, DeLa Cadena RA, Stadnicki A, (1998) The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol 16: 365-384.
10. Damas J, Garbacki N, Lefèbvre PJ, (2004) The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 20: 288-297 doi:10.1002/dmrr.489.
11. Hachem J-P, Wagberg F, Schmuth M, Crumrine D, Lissens W, et al. (2006) Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 126: 1609-1621 doi:10.1038/sj.jid.5700288.
12. Obiezu CV, Diamandis EP, (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224: 1-22 doi:10.1016/j.canlet.2004.09.024.
13. Young CY, Andrews PE, Tindall DJ, (1995) Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 16: 97-99.
14. Luo L-Y, Grass L, Diamandis EP, (2003) Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta 337: 115-126.
15. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP, (1999) Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 62: 251-259 doi:10.1006/geno.1999.6012.
16. Shih I-M, Salani R, Fiegl M, Wang T-L, Soosaipillai A, et al. (2007) Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 105: 501-507 doi:10.1016/j.ygyno.2007.01.018.
17. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, et al. (2001) Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84: 643-650 doi:10.1054/bjoc.2000.1649.
18. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, et al. (2009) Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 19: 1015-1021 doi:10.1111/IGC.0b013e3181ab597f.
19. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P, (2000) Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579-583.
20. Koh SCL, Razvi K, Chan YH, Narasimhan K, Ilancheran A, et al. (2011) The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet 284: 183-190 doi:10.1007/s00404-010-1605-z.
21. White NMA, Mathews M, Yousef GM, Prizada A, Popadiuk C, et al. (2009) KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer 101: 1107-1113 doi:10.1038/sj.bjc.6605280.
22. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Bellino R, et al. (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63: 807-811.
23. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, et al. (2007) Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 13: 1742-1748 doi:10.1158/1078-0432.CCR-06-2482.
24. Soslow RA, (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27: 161-174 doi:10.1097/PGP.0b013e31815ea812.
25. Ni X, Zhang W, Huang K-C, Wang Y, Ng S-K, et al. (2004) Characterisation of human kallikrein 6//protease M expression in ovarian cancer. Br J Cancer 91: 725-731.
26. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, et al. (2001) Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma. Clinical Cancer Research 7: 2372-2379.
27. Dorn J, Magdolen V, Gkazepis A, Gerte T, Harlozinska A, et al. (2011) Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann Oncol 22: 1783-1790 doi:10.1093/annonc/mdq701.
28. Diamandis EP, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, et al. (2003) Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol 24: 299-309 doi:10.1159/000076462.
29. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, et al. (2003) Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 307: 948-955.
30. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, et al. (2006) Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281: 32095-32112 doi:10.1074/jbc.M513138200.
31. Bayés A, Tsetsenis T, Ventura S, Vendrell J, Aviles FX, et al. (2004) Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem 385: 517-524 doi:10.1515/BC.2004.061.
32. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, et al. (2006) Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem 387: 677-685 doi:10.1515/BC.2006.086.
33. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, et al. (2006) Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 387: 817-824 doi:10.1515/BC.2006.104.
34. Liu XL, Wazer DE, Watanabe K, Band V, (1996) Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371-3379.
35. Huang W, Tian X-L, Wu Y-L, Zhong J, Yu L-F, et al. (2008) Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. World J Gastroenterol 14: 5810-5815.
36. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP, (2005) Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 26: 324-336 doi:10.1159/000089290.
37. Borgoño CA, Diamandis EP, (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4: 876-890 doi:10.1038/nrc1474.
38. Langdon SP, Lawrie SS, (2000) Establishment of Ovarian Cancer Cell Lines. Ovarian Cancer New Jersey Humana Press, Vol. 39 pp. 155-159 Available: http://www.springerlink.com/content/m3801lt69q5l11gk/#section=95017&page=1. Accessed 2011 Sep 11.
39. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC, (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042 doi:10.1016/j.ymthe.2004.08.013.
40. Buick RN, Pullano R, Trent JM, (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676.
41. Molthoff CF, Calame JJ, Pinedo HM, Boven E, (1991) Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 47: 72-79.
42. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, et al. (1985) Radiation survival parameters of antineoplastic drug-sensitive and-resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45: 2110-2115.
43. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, et al. (1992) Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 166: 676-684.
44. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, et al. (1998) The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782-4786.
45. Pace AM, Wong YH, Bourne HR, (1991) A mutant alpha subunit of Gi2 induces neoplastic transformation of Rat-1 cells. Proc Natl Acad Sci USA 88: 7031-7035.
46. Yousef GM, Polymeris M-E, Grass L, Soosaipillai A, Chan P-C, et al. (2003) Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 63: 3958-3965.
47. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, et al. (2000) Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 33: 369-375.
48. Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP, (2003) Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 49: 87-96.
49. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, et al. (2001) Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 47: 237-246.
50. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, et al. (2003) Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 49: 77-86.
51. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, et al. (2003) Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 63: 9032-9041.
52. Luo L-Y, Soosaipillai A, Grass L, Diamandis EP, (2006) Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. Tumour Biol 27: 227-234 doi:10.1159/000094693.
53. Lau DH, Lewis AD, Ehsan MN, Sikic BI, (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51: 5181-5187.
54. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP, (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 25: 193-199 doi:10.1159/000081102.
55. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, et al. (2006) Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem 281: 3116-3126 doi:10.1074/jbc.M510096200.
56. Nishibori M, Mori S, Takahashi HK, (2005) Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci 97: 25-30.
57. Prezas P, Arlt MJE, Viktorov P, Soosaipillai A, Holzscheiter L, et al. (2006) Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 387: 807-811 doi:10.1515/BC.2006.102.
58. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, et al. (2004) Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 122: 1235-1244 doi:10.1111/j.0022-202X.2004.22512.x.
59. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM, (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428-2432.
60. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, et al. (1980) Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40: 4658-4662.
61. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, et al. (1981) Prostate antigen: a new potential marker for prostatic cancer. Prostate 2: 89-96.
62. Sherer DM, Eliakim R, Abulafia O, (2000) The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50: 217-224.
63. Malden LT, Tattersall MH, (1986) Malignant effusions. Q J Med 58: 221-239.
64. Burleson KM, Boente MP, Pambuccian SE, Skubitz APN, (2006) Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med 4: 6 doi:10.1186/1479-5876-4-6.